Dr Piyush Vyas
Board certified clinical oncologist
Medical University of Warsaw
Dr Piyush Vyas is board certified clinical oncologist , presently persuing his next sub speciality training in clinical hematology.Being an academic teacher at Medical University of Warsaw, he is engaged in teaching oncology to undergradute and postgraduate students.Having had published reviews, research articles, case studies, poster presentations , Dr Piyush Vyas is well respected in academic circles of oncology . Dr Piyush Vyas is on editorial board / reviewer of many US and other international oncology/hematology/surgery journals. Dr Vyas is / was member of ASCO, ESMO, EHA, AACR, Polish Society of Clinical Oncology etc. as full member / associate member .Having had passed the most prestigious oncology exam the world over " European Society of Medical Oncology Exam" Dr Vyas has proved his world class clinical expertise / knowledge in managing oncology and haematological patients.Among others achievements.
Dr Piyush Vyas has credit to publish the first case study of a patient with metastatic duodenal carcinoma with concurrent immune thrombocytopenia treated with chemotherapy successfully, credit to publish a case study of a patient who seems to be longest survior( as per available literaturę) with stage IV adenocarcinoma of lung treated with tyrosine kinase inhibitor -Erlotinib . Being innovative in his approach Dr Piyush Vyas offered an economically very cost effective method of treating hepatocellular cancers with chemotherapy protocol FOLFOX4, very much appreciated approach in third world countries where targeted therapies are not widely available by publishing his marvellous article on hepatocellular cancer. He has been invited as speaker/ keynote speaker for international conferences .His poster presentations had been widely appreciated and had been very informative.Dr Piyush Vyas among others lastly presented an e poster as first author at Polish Annual Conference of Hematologists and Transfusion Medicine specialists - 2017, organised at Warsaw,Poland , where his group proved that not every thrombocytopenia patient should be disqualified as many of them can be immune thrombocytopenias, which can be effectively be treated.He is fluent in 4 languages , thus has a large geographical audience which he covers writting his articles in Polish, English etc.. His main research interest is in solid tumours with concurrent immune thrombocytopenias, solid tumours and in haematological malignancies.